Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

PURPOSE: Persistence of ligand-mediated androgen receptor signaling has been documented in castration-resistant prostate cancers (CRPCs). Abiraterone acetate (AA) is a potent and selective inhibitor of CYP17, which is required for androgen biosynthesis in the testes, adrenal glands, and prostate tis...

詳細記述

保存先:
書誌詳細
主要な著者: Danila, Daniel C., Morris, Michael J., de Bono, Johann S., Ryan, Charles J., Denmeade, Samuel R., Smith, Matthew R., Taplin, Mary-Ellen, Bubley, Glenn J., Kheoh, Thian, Haqq, Christopher, Molina, Arturo, Anand, Aseem, Koscuiszka, Michael, Larson, Steve M., Schwartz, Lawrence H., Fleisher, Martin, Scher, Howard I.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2010
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3040042/
https://ncbi.nlm.nih.gov/pubmed/20159814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.9259
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料